

Receipt date: 05/09/2007

Express Mail Label No.: EV942366585US

Date of Deposit: May 9, 2007

10594483 - GAU: 1621

Attorney Docket No. 24852-505 NATL

Page 1 of 2

Please type a plus sign (+) in this box

PTO/SB (12-97)
OMB 0651-0031Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number International Application Number I.A. Filing Date Priority Date First Named Inventor Group Art Unit / Conf. No.: Examiner Name Attorney Docket Number	10/594,483 PCT/US05/011463 April 5, 2005 April 5, 2004 Miller Not Yet Assigned S. Kumar Not Yet Assigned 24852-505 NATL
---	---	--

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
/S.K./	A1	4,522,811	06/11/85	Eppstein, et al.	514	2	07/08/82
	A2	5,369,108	11/29/94	Breslow, et al.	514	266	10/04/91
	A3	5,608,108	03/04/97	Marks, et al.	562	621	04/17/95
	A4	5,700,811	12/23/97	Breslow, et al.	514	314	05/19/94
	A5	5,932,616	08/03/99	Breslow, et al.	514	532	04/04/94
	A6	6,087,367	07/11/00	Breslow, et al.	514	266	05/18/99
	A7	6,511,990	01/28/03	Breslow, et al.	514	314	08/24/00
	A8	7,126,001	10/24/06	Breslow, et al.	546	171	10/25/02
	A8	2003/0235588	12/25/03	Richon, et al.	514	575	02/14/03
↓	A9	2004/0087657	05/06/04	Richon, et al.	514	575	10/16/02
↓	A10	2004/0266818	12/30/04	Breslow, et al.	514	310	04/01/04

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes No
/S.K./	B1	WO 97/11366	Merck & Co., Inc.	March 27, 1977	X
	B2	WO 98/48825	The Salk Institute for Biological Studies	November 5, 1998	X
	B3	WO 00/08048	Fujisawa Pharmaceuticals Co., Ltd.	February 17, 2000	X
	B4	WO 05/053610	Aton Pharma, Inc.	June 16, 2005	X
↓	B5	WO 05/097747	Aton Pharma, Inc.	October 20, 2005	X
↓	B6	WO 05/348800	Aton Pharma, Inc.	April 21, 2005	X

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
/S.K./	C1	Abe, E., et al., Proc. Natl. Acad. Sci. (USA) 78:4990-4994 (1981)
	C2	Andrews et al., International J. Parasitology 30:761-768 (2000)
	C3	Archer, S. et al., PNAS 95:6791-96 (1998)
	C4	Berge, et al., J. Pharm. Sci., 66:1-19 (1977).
	C5	Brosch et al., Plant Cell 7, 1941-1950 (1995)
	C6	Butler, L.M. et al., Cancer Res. 60:5165-5170 (2000)
	C7	Cohen, L.A. et al., Anticancer Research 19:4999-5006 (1999)
	C8	Cousens et al., J. Biol. Chem. 254,1716-1723 (1979)
	C9	Darkin-Rattray et al., Proc. Natl. Acad. Sci. USA 93,13143-13147 (1996)
↓	C10	Dressel, U. et al., Anticancer Research 20(2A):1017-22 (2000)
↓	C11	Ebert, P. S., et al. Cancer Res. 36: 1809-1813 (1976)

Receipt date: 05/09/2007

Express Mail Label No.: EV942366585US

Date of Deposit: May 9, 2007

10594483 - GAU: 1621

Attorney Docket No. 24852-505 NATL

Page 2 of 2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
/S.K./	C12	Finnin, M.S., et al., <i>Nature</i> 401:188-193 (1999)
	C13	Frey et al., <i>Bioorganic & Med. Chem. Lett.</i> , 12, 3443-3447 (2002)
	C14	Friend, C., et al., <i>Proc. Natl. Acad. Sci., U. S.</i> , 68:378-382 (1971)
	C15	Grunstein, M., <i>Nature</i> , 389: 349-52 (1997)
	C16	Guan et al., <i>Cancer Research</i> , 60, 749-755 (2000)
	C17	Hayashi, M., et al., <i>Gann</i> 70: 235-238 (1979)
	C18	Huberman, E. et al., <i>Proc. Natl. Acad. Sci. (USA)</i> 76: 1293-1297 (1979)
	C19	Kijima et al., <i>J Biol. Chem.</i> 268:22429-22435 (1993)
	C20	Kim et al., <i>Oncogene</i> , 18: 2461-2470 (1999)
	C21	Koghe et al., <i>Biochem. Pharmacol.</i> 56: 1359-1364 (1998)
	C22	Kwon et al., <i>PNAS</i> 95: 3356-3361 (1998)
	C23	Lea et al., <i>Anticancer Research</i> , 15, 879-873 (1995)
	C24	Lin, R.J. et al., <i>Nature</i> 391:811-14 (1998)
	C25	Lotem, J., et al., <i>Int. J. Cancer</i> 15: 731-740 (1975)
	C26	Lotem, J. et al., <i>Proc. Natl. Acad. Sci. (USA)</i> 76: 5158-5162 (1979)
	C27	Marks, P. et al., <i>Cancer Res.</i> 47:659 (1987)
	C28	Marks, P.A. et al., <i>J. Natl. Cancer Inst.</i> , 92:1210-1215 (2000)
	C29	McBain et al., <i>Biochem. Pharm.</i> 53: 1357-1368 (1997)
	C30	Metcalf, D., et al., <i>Science</i> , 229: 16-22 (1985)
	C31	Morin, M. J., et al., <i>Cancer Res.</i> 44: 2807-2812 (1984)
	C32	Nakajima et al., <i>Ex. Cell Res.</i> 241, 126-133 (1998)
	C33	Qiu et al., <i>Mol. Biol. Cell</i> 11, 2069-2083 (2000)
	C34	Reuben, R. C., et al., <i>Proc. Natl. Acad. Sci. (USA)</i> 73: 862-866 (1976)
	C35	Richon et al., <i>Proc. Natl. Acad. Sci. USA</i> , 93:5705-5708 (1996)
	C36	Richon, V. M. et al., <i>Proc. Natl. Acad. Sci., USA</i> , 95:3003-3007 (1998)
	C37	Sachs, L., <i>Nature (Lond.)</i> 274: 535 (1978)
	C38	Saito et al., <i>Proc. Natl. Acad. Sci. USA</i> 96, 4592-4597 (1999)
	C39	Scher, W. et al., <i>Exp. Hematol.</i> 11: 490-498 (1983)
	C40	Scher, W., et al., <i>Biochem. & Biophys. Res. Comm.</i> 109: 348-354) (1982)
	C41	Schwartz, E. L. et al., <i>Cancer Res.</i> 42: 2651-2655 (1982)
	C42	Schwartz, E. L., et al., <i>Cancer Res.</i> 43: 2725-2730 (1983)
	C43	Schwartz, E. L., et al., <i>Proc. Am. Assoc. Cancer Res.</i> 24: 18 (1983)
	C44	Su et al., <i>Cancer Research</i> , 60: 3137-3142 (2000)
	C45	Sugano, H., et al., <i>Bibl. Hematol.</i> 39: 943-954 (1973)
	C46	Takenaga, K., et al., <i>Cancer Res.</i> 40: 914-919 (1980)
	C47	Tanaka, M., et al., <i>Proc. Natl. Acad. Sci. (USA)</i> 72: 1003-1006 (1975)
	C48	Terada, M., et al., <i>Proc. Natl. Acad. Sci. (USA)</i> 75: 2795-2799 (1978)
	C49	Van Lint, C. et al., <i>Gene Expression</i> 5:245-53 (1996)
	C50	Wang et al., <i>Cancer Research</i> 59, 2766-2799 (1999)
✓	C51	Yoshida, M. et al., <i>J. Biol. Chem.</i> 265:17174-17179, (1990)
	C52	International Search Report for PCT/US05/011463 mailed July 26, 2005

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Shailendra Kumar/	Date Considered	02/03/2011
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.